Section 3.4: Pharmacoeconomic Principles & Cost-Benefit Analysis

Pharmacoeconomic Principles & Cost-Benefit Analysis

Introduction to Pharmacoeconomics

Pharmacoeconomics is the branch of health economics that identifies, measures, and compares the costs (resource inputs) and consequences (therapeutic outcomes) of pharmaceutical products, programs, and services. As healthcare expenditures escalate, pharmacoeconomic analysis provides a framework for optimal resource allocation. These evaluations help clinical pharmacists, formulary committees, and national regulators determine if the clinical benefits of a new medication justify its financial impact on the healthcare system.

Classification of Costs

Costs in health economic evaluations are categorized based on their relationship to clinical delivery and society:

• Direct Medical Costs: Direct financial resources spent on clinical care (e.g., drug acquisition costs, physician consultation fees, hospitalization days, diagnostic lab tests, clinical nursing care).
• Direct Non-Medical Costs: Expenditures incurred by the patient to receive care, which are not directly medical (e.g., transportation costs to the hospital, parking fees, specialized dietary needs, lodging near treatment centers).
• Indirect Costs: Economic losses resulting from patient morbidity and mortality, including lost productivity, missed workdays, and early retirement.
• Intangible Costs: Non-monetary burdens representing patient physical pain, mental suffering, anxiety, and decreased quality of life. These are difficult to quantify.

Pharmacoeconomic Methodologies

Four standardized pharmacoeconomic methodologies are utilized in health technology assessments:

1. Cost-Minimization Analysis (CMA)

• Assumptions: The clinical safety and efficacy outcomes of the compared therapeutic interventions are documented to be equivalent (e.g., comparing brand-name drugs with generic alternatives, or two drugs in the same class with identical clinical profiles).
• Measurement: Costs are measured in monetary units (e.g., Saudi Riyals - SAR). Outcomes are assumed equal and not evaluated separately.
• Objective: Identify the least expensive treatment option.

2. Cost-Effectiveness Analysis (CEA)

• Assumptions: The clinical outcomes of the compared interventions differ, but they can be measured in identical, natural clinical units (e.g., mmHg reduction in blood pressure, percentage of patients cured, life-years gained).
• Measurement: Costs are measured in monetary units. Outcomes are measured in natural health units.
• Metric: The Incremental Cost-Effectiveness Ratio (ICER): $\text{ICER} = \frac{\text{Cost}_{\text{Drug A}} - \text{Cost}_{\text{Drug B}}}{\text{Effect}_{\text{Drug A}} - \text{Effect}_{\text{Drug B}}}$ The ICER represents the additional cost required to achieve one additional unit of clinical benefit.

3. Cost-Utility Analysis (CUA)

• Assumptions: Adjusts survival (quantity of life) by a utility weight reflecting the quality of life during that survival time.
• Measurement: Costs are measured in monetary units. Outcomes are measured in Quality-Adjusted Life Years (QALYs) or Disability-Adjusted Life Years (DALYs).
  • QALY Calculation: Calculated by multiplying the years of life gained by a utility score ranging from 0 (representing death) to 1 (representing perfect health). For example, if a drug extends a patient's life by 5 years, but the patient lives with a utility score of 0.6 due to chemotherapy side effects, the total QALYs gained are: $5 \text{ years} \times 0.6 = 3.0 \text{ QALYs}$
• Utility Assessment: Employs standardized instruments like the EQ-5D to measure patient utility states.
• Objective: Highly useful for evaluating treatments that improve quality of life rather than extending survival (e.g., treatments for chronic arthritis or cosmetic dermatological conditions).

4. Cost-Benefit Analysis (CBA)

• Assumptions: Both inputs and outcomes are valued in monetary terms. This allows the comparison of completely different types of healthcare programs (e.g., allocating funds to an immunization program vs. building a new stroke unit).
• Measurement: Costs and outcomes are measured in monetary units. This method requires controversial valuations of health states, often established using Willingness-to-Pay (WTP) surveys.
• Metric: Net Benefit (Total Benefit $-$ Total Cost) or Cost-Benefit Ratio (Total Benefit $/$ Total Cost).

Summary of Pharmacoeconomic Methodologies

Pharmacoeconomics and the SFDA Formulary Listing

In Saudi Arabia, the SFDA integrates pharmacoeconomic reviews into the drug registration and pricing process. For a new drug to be listed on the national formulary and reimbursed by public health insurance (NHIC) or utilized in government hospital networks (like MOH and military hospitals), manufacturers must submit health technology assessment (HTA) dossiers.

• Value-Based Pricing: The SFDA evaluates the cost-effectiveness of new drugs relative to standard therapies already available in Saudi Arabia. Decisions are guided by a threshold representing the maximum amount the healthcare system is willing to pay for a unit of health effect (e.g., per QALY).
• Budget Impact Analysis (BIA): Along with cost-effectiveness, the SFDA assesses the total financial burden the drug will impose on the healthcare system over a 3-to-5-year horizon. A drug may be cost-effective but rejected or restricted if its budget impact is unaffordable. Policymakers use this information to negotiate price reductions or risk-sharing agreements with manufacturers.